Charles Schwab’s Myovant Sciences Ltd. MYOV Stock Holding History

Charles Schwab’s Portfolio MYOV Stock Details MYOV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-225,485	Closed	-$6.08M	–	3614
2022 Q4	$6.08M	Buy	225,485 +7,819	+4%	+$206K	﹤0.01%	2121
2022 Q3	$3.91M	Sell	217,666 -5,056	-2%	-$80.7K	﹤0.01%	2351
2022 Q2	$2.77M	Buy	222,722 +4,693	+2%	+$51.8K	﹤0.01%	2455
2022 Q1	$2.9M	Buy	218,029 +5,868	+3%	+$78.7K	﹤0.01%	2515
2021 Q4	$3.3M	Buy	212,161 +3,339	+2%	+$63.7K	﹤0.01%	2547
2021 Q3	$4.69M	Buy	208,822 +16,007	+8%	+$351K	﹤0.01%	2408
2021 Q2	$4.39M	Buy	192,815 +4,842	+3%	+$102K	﹤0.01%	2414
2021 Q1	$3.87M	Buy	+187,973	New	+$4.28M	﹤0.01%	2418
2017 Q2	–	Sell	-16,900	Closed	-$199K	–	3154
2017 Q1	$199K	Hold	16,900	–	–	﹤0.01%	2933
2016 Q4	$211K	Buy	+16,900	New	+$196K	﹤0.01%	2949

Other funds holding MYOV

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Charles Schwab's MYOV Position: Q1 2023 in Review

Charles Schwab sold out of Myovant Sciences Ltd. (MYOV) in Q1 2023, closing a stake of 225,485 shares — an estimated $6.08M sold.

Charles Schwab first reported a position in MYOV in Q4 2016 and held it in 10 quarters. The position peaked at $6.08M in Q4 2022. 2 funds tracked by Wall St. Rank hold MYOV as of Q1 2023.

Charles Schwab reported no remaining Myovant Sciences Ltd. position as of Q1 2023 after selling out during the quarter.
Charles Schwab sold 225,485 Myovant Sciences Ltd. shares in Q1 2023, an estimated $6.08M.
Charles Schwab first reported a position in Myovant Sciences Ltd. in Q4 2016 and held it in 10 quarters.
Charles Schwab's Myovant Sciences Ltd. position peaked at $6.08M in Q4 2022.
2 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q1 2023.

Based on Charles Schwab's 13F filing for Q1 2023, filed 12 May 2023.